Goserelin Acetate 中文名称: 醋酸戈舍瑞林

别名: Goserelin Acetate; ICI-118630; ICI118630; ICI 118630; brand name: Zoladex

目录号: V21736 纯度: ≥98%

COA 产品数据产品说明书 SDS

戈舍瑞林是一种合成的黄体生成素释放激素 (LHRH) 十肽类似物，具有抗肿瘤活性。

Goserelin Acetate CAS号: 145781-92-6
产品类别: GnRH Receptor

产品仅用于科学研究，不针对患者销售

规格	价格	库存	数量
5mg
10mg
25mg
50mg
100mg
250mg
500mg
Other Sizes

加入购物车结帐大包装询价

020-31522723 sales@invivochem.cn

Other Forms of Goserelin Acetate:

点击了解更多

InvivoChem产品被CNS等顶刊论文引用

Nature 2025, 643(8070):192-200.

Nature 2024 Dec 18.

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nat Neurosci 2024, 27:1468-1474.

Science Adv 2025, 11(33):eadr5199.

Nat Metab 2024, 6: 1108-1127.

Cell Stem Cell 2024, 31:106-126.e13.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

Immunity 2024,57:2651-2668.e12.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

纯度/质量控制文件

批次：

纯度: ≥98%

COA

MSDS

产品说明书

产品描述
生物活性&实验参考方法
化学信息
溶解度数据
计算器
临床试验信息
生物数据图片
相关产品

产品描述

戈舍瑞林是一种合成的黄体生成素释放激素 (LHRH) 十肽类似物，具有抗肿瘤活性。戈舍瑞林结合并激活垂体促性腺激素释放激素 (GnRH) 受体。长期服用戈舍瑞林会抑制垂体促性腺激素的分泌，从而降低睾酮（男性）和雌二醇（女性）的水平。以储库制剂形式施用该药物可能会导致性激素敏感肿瘤的消退以及性器官大小和功能的减少。

生物活性&实验参考方法

靶点	GnRH
体外研究 (In Vitro)	戈舍瑞林 (1 nM-1 mM；48-72 小时) 促进 EOC 细胞的表达[1]。戈舍瑞林 (100 μM；24-72 小时) 调节 SKOV3-ip 细胞中人肝癌相关基因的表达[1]。 (100 μM；24-72 小时)通过 PI3K/AKT 信号负载上调 FOXO1 促进 EOC 细胞炎症[1]。细胞凋亡分析[1] Cell Line: SKOV3 cells, SKOV3-ip cells, A2780 cells ( human EOC cell line)浓度：1 nM、10 nM、100 nM、1 μM、10 μM、100 μM、1 mM 孵育时间：48 小时、72 小时结果：显着增加 SKOV3-ip、SKOV3 和 A2780 细胞的总凋亡率。 Western Blot 分析[1] 细胞系：SKOV3 细胞、SKOV3-ip 细胞、A2780 细胞（人 EOC 细胞系）浓度：1 nM、10 nM、100 nM、1 μM、10 μM、100 μM、1 mM 孵育时间： 48小时、72小时结果：100μM时，cleaved-caspase-3和cleaved-PARP的表达明显增加。 RT-PCR[1] 细胞系：SKOV3-ip 细胞浓度：100 μM 孵育时间：24 小时、48 小时、72 小时结果：人类凋亡相关基因的表达受到调节
体内研究 (In Vivo)	醋酸戈舍瑞林（100 μg；皮下注射；每天；持续19天）显着增加皮下异种移植肿瘤中阳极细胞的比例[1]。动物模型：五周龄无特定病原体（SPF）雌性裸鼠（ 18-20 g)，皮下异种移植肿瘤模型[1] 剂量：100 µg/小鼠给药方式：皮下注射，每天，持续 19 天结果：显着增加皮下异种移植肿瘤中凋亡细胞的比例
细胞实验	细胞系：SKOV3 细胞、SKOV3-ip 细胞、A2780 细胞（人 EOC 细胞系）浓度：1 nM、10 nM、100 nM、1 μM、10 μM、100 μM、1 mM 孵育时间： 48小时、72小时结果：SKOV3-ip、SKOV3、A2780细胞总凋亡率显着增加
动物实验	五周龄无特定病原体（SPF）雌性裸鼠（18-20克），皮下异种移植瘤模型 100微克/只小鼠每日皮下注射，持续19天
参考文献	[1]. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway. Oncol Rep. 2018 Mar; 39(3): 1034–1042. [2]. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923-32.
其他信息	根据州或联邦政府的标签要求，戈舍瑞林醋酸盐可引起发育毒性、女性生殖毒性和男性生殖毒性。戈舍瑞林醋酸盐是促黄体生成素释放激素 (LHRH) 合成十肽类似物的醋酸盐。男性长期持续服用戈舍瑞林会导致垂体促性腺激素分泌受到抑制，从而导致睾酮生成显著下降；女性长期服用会导致雌二醇生成减少。(NCI04) 戈舍瑞林是一种合成的长效促性腺激素释放激素激动剂。它用于治疗前列腺恶性肿瘤、子宫肌瘤和转移性乳腺癌。另见：戈舍瑞林（含有活性部分）。

*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性

化学信息 & 存储运输条件

分子式	C61H88N18O16
分子量	1329.485
精确质量	1328.66
元素分析	C, 55.11; H, 6.67; N, 18.96; O, 19.25
CAS号	145781-92-6
相关CAS号	Goserelin; 65807-02-5
PubChem CID	16052011
外观&性状	White to off-white solid powder
密度	1.5±0.1 g/cm3
沸点	1695.5ºC at 760mmHg
熔点	>190°C (dec.)
蒸汽压	0mmHg at 25°C
折射率	1.692
LogP	-0.95
tPSA	493.39
氢键供体(HBD)数目	18
氢键受体(HBA)数目	18
可旋转键数目(RBC)	32
重原子数目	95
分子复杂度/Complexity	2590
定义原子立体中心数目	9
SMILES	O=C(N[C@H](C(N[C@@H](CC1=CC=C(O)C=C1)C(N[C@H](COC(C)(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N2CCC[C@H]2C(NNC(N)=O)=O)=O)=O)=O)=O)=O)CO)[C@@H](NC([C@H](CC3=CN=CN3)NC([C@@H](N4)CCC4=O)=O)=O)CC5=CNC6=C5C=CC=C6.CC(O)=O
InChi Key	IKDXDQDKCZPQSZ-JHYYTBFNSA-N
InChi Code	InChI=1S/C59H84N18O14.C2H4O2/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38;1-2(3)4/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90);1H3,(H,3,4)/t38-,39-,40-,41-,42-,43-,44-,45+,46-;/m0./s1
化学名	acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
别名	Goserelin Acetate; ICI-118630; ICI118630; ICI 118630; brand name: Zoladex
HS Tariff Code	2934.99.9001
存储方式	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意：请将本产品存放在密封且受保护的环境中，避免吸湿/受潮。
运输条件	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

溶解度数据

溶解度 (体外实验)	H2O: ~100 mg/mL (~75.2 mM) DMSO: ≥ 28 mg/mL (~21.1 mM)
溶解度 (体内实验)	配方 1 中的溶解度: ≥ 2.08 mg/mL (1.56 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将100 μL 20.8 mg/mL澄清DMSO储备液加入400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。配方 2 中的溶解度:* ≥ 2.08 mg/mL (1.56 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将 100 μL 20.8 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。 View More* 配方 3 中的溶解度: 2.08 mg/mL (1.56 mM) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将 100 μL 20.8 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。配方 4 中的溶解度: 50 mg/mL (37.61 mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶. 请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、以上所有助溶剂都可在 Invivochem.cn网站购买。

溶解度 (体外实验)

H2O: ~100 mg/mL (~75.2 mM)
DMSO: ≥ 28 mg/mL (~21.1 mM)

溶解度 (体内实验)

配方 1 中的溶解度: ≥ 2.08 mg/mL (1.56 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 20.8 mg/mL澄清DMSO储备液加入400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

配方 2 中的溶解度: ≥ 2.08 mg/mL (1.56 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 20.8 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

View More

配方 3 中的溶解度: 2.08 mg/mL (1.56 mM) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 20.8 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。

配方 4 中的溶解度: 50 mg/mL (37.61 mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶.

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、以上所有助溶剂都可在 Invivochem.cn网站购买。

制备储备液		1 mg	5 mg	10 mg
	1 mM	0.7522 mL	3.7608 mL	7.5217 mL
	5 mM	0.1504 mL	0.7522 mL	1.5043 mL
	10 mM	0.0752 mL	0.3761 mL	0.7522 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器

质量

浓度

体积

分子量*

计算重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

计算制备已知体积和浓度的溶液所需的化合物的质量
计算将已知质量的化合物溶解到所需浓度所需的溶液体积
计算特定体积中已知质量的化合物产生的溶液的浓度

参见示例

使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？

在分子量（MW）框中输入350.26
在“浓度”框中输入10，然后选择正确的单位（mM）
在“体积”框中输入5，然后选择正确的单位（mL）
单击“计算”按钮
答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。

浓度 (起始)

体积 (起始)

浓度 (终)

体积 (终)

计算重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：

在C1框中输入10，然后选择正确的单位（mM）
在C2框中输入25，然后选择正确的单位（μM）
在V2框中输入25，然后选择正确的单位（mL）
单击“计算”按钮
答案62.5μL（0.1 ml）出现在V1框中

分子式

分子量

g/mol

计算重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4 c12h18n3o4
计算化合物摩尔质量（分子量）的说明：

要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。

分子质量、分子量、摩尔质量和摩尔量的定义：

分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。

配液体积

质量

配液浓度

计算重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

输入试剂的质量、所需的配液浓度以及正确的单位
单击“计算”按钮
答案显示在体积框中

动物体内实验配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg

动物平均体重 g

每只动物给药体积 μL

动物数量

第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。

% DMSO

% Tween 80

% ddH₂O

计算重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意： (1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
CTID: NCT03361735
Phase: Phase 2 Status: Active, not recruiting
Date: 2024-12-02

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
CTID: NCT01786265
Phase: Phase 2 Status: Active, not recruiting
Date: 2024-11-29

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
CTID: NCT03070886
Phase: Phase 2/Phase 3 Status: Active, not recruiting
Date: 2024-11-29

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
CTID: NCT02115282
Phase: Phase 3 Status: Active, not recruiting
Date: 2024-11-13

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
CTID: NCT02003209
Phase: Phase 3 Status: Active, not recruiting
Date: 2024-11-13

View More

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
CTID: NCT04423211
Phase: Phase 3 Status: Recruiting
Date: 2024-11-05

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
CTID: NCT02023463
Phase: Phase 1 Status: Active, not recruiting
Date: 2024-10-23

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
CTID: NCT03942653
Phase: Phase 2 Status: Recruiting
Date: 2024-10-15

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
CTID: NCT03678025
Phase: Phase 3 Status: Recruiting
Date: 2024-08-16

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
CTID: NCT04484818
Phase: Phase 3 Status: Active, not recruiting
Date: 2024-07-03

Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer
CTID: NCT03936933
Phase: Phase 3 Status: Recruiting
Date: 2024-05-17

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
CTID: NCT02278185
Phase: Phase 2 Status: Active, not recruiting
Date: 2024-05-06

To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer
CTID: NCT06385847
Phase: Phase 2 Status: Recruiting
Date: 2024-04-26

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
CTID: NCT06282588
Phase: Phase 2/Phase 3 Status: Recruiting
Date: 2024-02-28

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
CTID: NCT00544830
Phase: Phase 2 Status: Active, not recruiting
Date: 2024-02-20

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
CTID: NCT04734730
Phase: Phase 2 Status: Recruiting
Date: 2024-01-03

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
CTID: NCT01674140
Phase: Phase 3 Status: Active, not recruiting
Date: 2023-12-20

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
CTID: NCT04455750
Phase: Phase 3 Status: Active, not recruiting
Date: 2023-12-04

High-Dose Brachytherapy in Treating Patients With Prostate Cancer
CTID: NCT02346253
Phase: N/A Status: Active, not recruiting
Date: 2023-11-22

RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
CTID: NCT00541047
Phase: Phase 3 Status: Completed
Date: 2023-11-13

To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone
CTID: NCT05898321
Phase: N/A Status: Not yet recruiting
Date: 2023-06-12

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
CTID: NCT02058706
Phase: Phase 2 Status: Completed
Date: 2023-05-10

Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose
CTID: NCT03440879
Phase: N/A Status: Terminated
Date: 2023-03-27

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
CTID: NCT00055731
Phase: Phase 3 Status: Completed
Date: 2023-01-18

Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
CTID: NCT05212857
Phase: Phase 2 Status: Unknown status
Date: 2022-03-16

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
CTID: NCT02626507
Phase: Phase 1 Status: Unknown status
Date: 2022-02-09

Goserline Acetate VS Dienogest in Endometriosi
CTID: NCT05013242
Phase: Phase 4 Status: Unknown status
Date: 2021-10-20

Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer
CTID: NCT04060043
PhaseEarly Phase 1 Status: Completed
Date: 2021-05-10

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.
CTID: NCT03658213
Phase: Phase 3 Status: Withdrawn
Date: 2021-05-10

Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
CTID: NCT00104715
Phase: Phase 3 Status: Completed
Date: 2021-02-21

BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH
CTID: NCT04203212
Phase: Status: Completed
Date: 2021-01-12

Management of Castration-Resistant Prostate Cancer With Oligometastases
CTID: NCT02685397
Phase: Phase 2/Phase 3 Status: Recruiting
Date: 2020-10-20

A Phase II Study of Androgen Deprivation T
A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-adrogen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomy (SAVE)
CTID: null
Phase: Phase 2 Status: Trial now transitioned
Date: 2019-02-04

Selecting the Optimal position of CDK4/6 Inhibitors in HR+ Advanced breast cancer: the SONIA trial
CTID: null
Phase: Phase 3 Status: Ongoing
Date: 2017-09-29

A phase 2 Randomized Open-Label Study of Oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer
CTID: null
Phase: Phase 2 Status: Ongoing, Trial now transitioned, Completed
Date: 2017-09-21

A Phase 2, international, multicenter, open-labeled, randomised trial of palbociclib and fulvestrant versus standard oral capecitabine in patients with hormone receptor positive / HER2 negative advanced breast cancer and documented endocrine resistance (PASIPHAE)
CTID: null
Phase: Phase 2 Status: GB - no longer in EU/EEA, Prematurely Ended
Date: 2017-08-14

A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2017-07-19

Chemoprevention in BRCA1 mutation carriers - a proof of concept study
CTID: null
Phase: Phase 2 Status: Prematurely Ended
Date: 2016-06-23

An open label, multiple dose, Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy of AMW goserelin 3.6 mg implant in its application system
CTID: null
Phase: Phase 3 Status: Completed
Date: 2015-12-14

Neo-adjuvant Androgen Deprivation Therapy, Pelvic Radiotherapy and RADium-223 for new presentation T1-4 N0/1 M1B adenocarcinoma of prostate (ADRRAD Trial)
CTID: null
Phase: Phase 2 Status: GB - no longer in EU/EEA
Date: 2015-07-13

Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma
CTID: null
Phase: Phase 2 Status: Completed
Date: 2015-05-04

Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male patients with prostate cancer
CTID: null
Phase: Phase 3 Status: Completed
Date: 2015-01-16

A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer
CTID: null
Phase: Phase 3 Status: Ongoing, Completed
Date: 2014-12-19

A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in
CTID: null
Phase: Phase 2 Status: Completed
Date: 2012-08-27

A PHASE IV, RANDOMISED, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE IMPACT ON DISEASE CONTROL, SAFETY, PATIENT AND CLINICIAN EXPERIENCE OF CHANGING PATIENTS WITH ADVANCED PROSTATE CANCER FROM A 3-MONTHLY LHRH AGONIST TO 6-MONTHLY INJECTIONS OF DECAPEPTYL® SR 22.5 MG
CTID: null
Phase: Phase 4 Status: Prematurely Ended
Date: 2012-05-01

A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED
CTID: null
Phase: Phase 3 Status: Ongoing
Date: 2010-11-08

A Randomised Controlled Trial to Determine the Effect of Decapeptyl on Reduction of Prostate Volume Pre-Radiotherapy Compared with Standard Therapy (Zoladex)
CTID: null
Phase: Phase 2 Status: Completed
Date: 2010-08-17

An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy
CTID: null
Phase: Phase 3 Status: Completed
Date: 2009-07-17

OPEN LABEL, MULTICENTER STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF GOSERELIN 10.8 mg IMPLANT HEXAL IN PATIENTS WITH ADVANCED HORMONE DEPENDENT PROSTATE CANCER
CTID: null
Phase: Phase 3 Status: Completed
Date: 2008-12-18

Radiotherapy and Androgen Deprivation in Combination After Local Surgery. A randomised controlled trial for patients with prostate cancer.
CTID: null
Phase: Phase 3 Status: GB - no longer in EU/EEA, Completed
Date: 2007-04-27

Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer
CTID: null
Phase: Phase 3 Status: Completed
Date: 2007-02-16

ESTUDIO MULTICÉNTRICO FASE II DE DISTRIBUCIÓN ALEATORIA, PARA EVALUAR LA EFICACIA DE TRATAMIENTO NEOADYUVANTE SELECTIVO SEGÚN SUBTIPO INMUNOHISTOQUÍMICO EN CÁNCER DE MAMA HER2 NEGATIVO
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2006-12-01

An open label, parallel group, Phase III clinical study in patients with advanced prostate cancer suitable for hormonal manipulation to demonstrate the non-inferiority of a new three-month Novosis Goserelin 10.8 mg implant versus the reference product Zoladex® 10.8 mg and to show the comparability of the Novosis Goserelin 3.6 mg implant applied every 28 days for three months with the new three-month Novosis Goserelin 10.8 mg implant
CTID: null
Phase: Phase 3 Status: Completed
Date: 2006-11-04

PATCH
CTID: null
Phase: Phase 2, Phase 3 Status: GB - no longer in EU/EEA
Date: 2005-11-23

A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer.
CTID: null
Phase: Phase 3 Status: Ongoing, Completed
Date: 2005-05-12

Prospective randomized multicenter study to prevent chemotherapy induced ovarian failure with the GnRH-Agonist Goserelin in young hormone insensitive breast cancer patients receiving anthracycline containing (neo-)adjuvant chemotherapy
CTID: null
Phase: Phase 2 Status: Completed
Date: 2005-01-13

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
CTID: null
Phase: Phase 2, Phase 3 Status: GB - no longer in EU/EEA
Date: 2004-10-04
None
CTID: jRCT2080220535
Phase: Status:
Date: 2008-03-25

生物数据图片

Flow cytometric analysis of pro-apoptotic effect by goserelin on EOC cells. Oncol Rep . 2018 Mar;39(3):1034-1042.
Hoechst staining analysis of the pro-apoptotic effect by goserelin on EOC cells. Oncol Rep . 2018 Mar;39(3):1034-1042.
Expression of human apoptosis-related genes regulated by goserelin in SKOV3-ip cells. Oncol Rep . 2018 Mar;39(3):1034-1042.